Published on 6 Apr 2024 on Simply Wall St. via Yahoo Finance
Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this...
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have had an unfortunate run in the last three years. Unfortunately, they have held through a 65% decline in the share price in that time. And the ride hasn't got any smoother in recent times over the last year, with the price 31% lower in that time. Even worse, it's down 17% in about a month, which isn't fun at all.
After losing 9.9% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.
See our latest analysis for Intellia Therapeutics